Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Array Technologies is trading at $3.43, down 7% on the week and 22% over the past month, with short sellers rebuilding positions, analysts cutting targets again, and passive index funds now a likely source of forced selling into year-end.
Short interest has climbed to 25.8% of free float, up 6.7% on the week and 33% over the past month. That is a meaningful rebuild from mid-September levels, when shorts were closer to 19% of float. The ORTEX short score holds at 74.1, a level it has barely moved from across the past two weeks, signalling that the aggregate short positioning signal remains at the extreme end of the range. Availability has dropped to zero. Every share in the lending pool is currently lent out, matching the 52-week floor. Against that, the cost to borrow remains subdued at 0.93%, down about 11% on the week, which means new short positions can still be put on cheaply despite the tight availability. Options traders are not pressing the bearish case in kind: the put/call ratio is 0.19, well below its 20-day average of 0.22 and near the 52-week low of 0.16. The contrast matters. The short book is heavy and growing, but options buyers are skewing toward calls, not hedging further downside.
The Street has spent the past week cutting targets with little sign of a floor. Mizuho upgraded to Outperform on October 15 while simultaneously lowering its target from $7 to $5. Morgan Stanley trimmed from $8 to $6 on October 14, and Barclays moved from $8 to $4 the same day. Susquehanna cut from $6.75 to $4. The consensus remains hold, with 10 buys against 13 holds, and the mean target at $7.44 is more than double the current price of $3.43. That gap has been wide for weeks. The pace of cuts since September suggests targets are still chasing the stock lower rather than anchoring it. The EPS momentum factor score is strong at 87 over 30 days, and forward earnings estimates are rising on a year-on-year basis, but the short score rank in the 3rd percentile and days-to-cover rank in the 6th percentile reflect how far the positioning picture is from the fundamental one.
The index deletion risk is an underappreciated mechanical pressure. ORTEX puts the probability of ARRY being removed from the CRSP US Small index at the December 2026 quarterly review at 81%, with the rank date on December 4. That would require index trackers to sell roughly $8M of stock, about 0.3 days of normal volume. The stock is already 56.9% below the exit line price of $5.60. Separately, ORTEX puts a 51% probability on deletions from the MSCI World Small, MSCI USA IMI, MSCI USA Small, and MSCI World IMI at the November 2026 quarterly review, with the rank date falling tomorrow, October 19. Those four deletions combined represent up to $60M in potential selling flow, roughly 2.4 days of normal volume in aggregate. The deciding price for the November reviews is $4.10. The stock needs to close above that level to change the MSCI call, and it is currently 16% below it.
Peers offer no relief. SHLS fell 18% on the week and AMSC lost 16%. NXT, the closest competitor in utility-scale solar tracking, dropped 7%. The selloff in solar and clean energy hardware is broad, but ARRY's 25.8% short interest against a sector where most names are in single digits shows the market has taken a distinctly more aggressive view of this name specifically.
The next earnings print is scheduled for November 5. The last result on August 5 sent the stock down 12.6% on the day and 13.6% over the following five days. The setup heading into November is: heavy short positioning, zero borrow availability, falling analyst targets, a potential MSCI rank date tomorrow, and an earnings date three weeks out. What to watch is whether the stock can hold above $4.10 before October 19, which determines whether the MSCI deletion forecasts become announcements in November.
See the live data behind this article on ORTEX.
Open ARRY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.